Charles K. Gayer serves as the Chief Commercial Officer at BioCryst Pharmaceuticals Inc., a position he has held since joining the company in 2019. In this role, Gayer is responsible for overseeing the company's global commercial strategy and operations, which includes the launch and marketing of BioCryst's innovative therapies. His leadership has been instrumental in driving the commercial success of ORLADEYO®, a groundbreaking oral treatment for hereditary angioedema (HAE), which was approved by the FDA in 2020. Gayer's strategic vision and deep understanding of the pharmaceutical market have been key factors in positioning BioCryst as a leader in the development of novel treatments for rare diseases. Prior to joining BioCryst, Gayer amassed an impressive track record in the pharmaceutical industry, with over 25 years of experience in various leadership roles. He previously served as the Senior Vice President and Chief Commercial Officer at TESARO, Inc., where he played a pivotal role in the successful launch of ZEJULA®, a PARP inhibitor for ovarian cancer. Before TESARO, Gayer held senior positions at Millennium: The Takeda Oncology Company and Schering-Plough Corporation, where he demonstrated his expertise in building and leading high-performing commercial teams. Gayer's career has been marked by his ability to navigate complex markets and deliver successful product launches, making him a valuable asset to BioCryst Pharmaceuticals. Gayer's contributions to BioCryst extend beyond his commercial leadership. He is known for his commitment to fostering a culture of innovation and collaboration within the company. Under his guidance, BioCryst has strengthened its partnerships with patient advocacy groups and healthcare providers, ensuring that the company's therapies reach those who need them most. Gayer's strategic foresight and dedication to improving patient outcomes have solidified his reputation as a respected leader in the pharmaceutical industry, and his ongoing work at BioCryst continues to drive the company's mission to develop transformative treatments for rare diseases.